
    
      The central aim of this study is to investigate the safety, tolerability, and indicative
      efficacy of a single dose of a phage therapy combination product, BACTELIDE, as an adjunct to
      standard therapy in participants presenting with a Stage II, III or IV pressure injuries with
      positive wound cultures for S. aureus, P. aeruginosa, or K. pneumoniae at screening.
    
  